Melanoma staging employs TNM classification system (Tumor, Node, Metastasis) combining primary tumor characteristics (thickness, ulceration, mitotic rate), regional lymph node involvement, and distant metastases to predict prognosis and guide treatment decisions. The American Joint Committee on Cancer (AJCC) 8th edition (2017) provides evidence-based staging incorporating molecular markers (tumor-infiltrating lymphocytes, sentinel lymph node micrometastasis size) and improved risk stratification compared to prior editions. Accurate staging requires comprehensive clinicopathologic evaluation including primary tumor depth (Breslow thickness), lymph node assessment (sentinel lymph node biopsy or imaging), and whole-body imaging for distant metastases in high-risk patients. Understanding staging system enables prognostication, comparative outcomes research, and evidence-based treatment recommendations.

TNM Components and Definitions

T Stage (Primary Tumor): Based on Breslow thickness, ulceration, mitotic rate, and Clark level. TX: primary tumor cannot be assessed; T0: no evidence of primary tumor; Tis: melanoma in situ. T1: <1 mm thickness (T1a no ulceration, <1 mitosis/mm²; T1b ulceration or ≥1 mitosis/mm²). T2: 1-2 mm (T2a no ulceration; T2b ulceration). T3: 2-4 mm (T3a no ulceration; T3b ulceration). T4: >4 mm (T4a no ulceration; T4b ulceration).

Breslow thickness is single strongest prognostic factor; each millimeter increase substantially worsens prognosis. Ulceration indicates aggressive biology and upstages lesions. Mitotic rate and Clark level are incorporated as secondary stratifiers when thickness alone is insufficient for risk assessment.

N Stage (Regional Lymph Nodes): Based on number of positive lymph nodes, size of nodal disease (micrometastases <0.1 mm vs. macroscopic >0.1 mm), and presence of in-transit metastases or satellite lesions. N0: no regional node metastases. N1: 1 node (N1a micrometastases; N1b macroscopic). N2: 2-3 nodes (N2a micrometastases; N2b macroscopic; N2c in-transit metastases/satellites without node involvement). N3: ≥4 nodes, or matted nodes, or in-transit metastases with node involvement.

Sentinel lymph node biopsy identifies occult nodal disease in 5-10% of intermediate-thickness melanomas, converting N0 stage to N1/N2, substantially worsening prognosis. SLN status directly guides adjuvant therapy decisions.

M Stage (Distant Metastases): M0: no distant metastases. M1a: distant skin/soft tissue/lymph node metastases. M1b: lung metastases. M1c: non-CNS visceral metastases. M1d: CNS (brain) metastases. Metastasis location substantially influences prognosis: lymph node/skin metastases carry better prognosis than visceral disease; CNS involvement carries worst prognosis.

Overall Stage Grouping

Stage 0: Melanoma in situ (100% 5-year survival). Stage IA: T1a N0 M0 (97%). Stage IB: T1b N0 M0 or T2a N0 M0 (92%). Stage IIA: T2b N0 M0 or T3a N0 M0 (81%). Stage IIB: T3b N0 M0 or T4a N0 M0 (70%). Stage IIC: T4b N0 M0 (53%). Stage III: Any T with regional node involvement or in-transit metastases (40-78% depending on N stage). Stage IV: Distant metastases (7-50% depending on M stage and treatment).

Sentinel Lymph Node Biopsy and Interpretation

Indications: SLN biopsy is recommended for intermediate-thickness melanomas (1-4 mm). Thin melanomas (<1 mm) may warrant SLN consideration with high-risk features (ulceration, mitotic rate ≥1/mm², level IV-V, age <40). Thick melanomas (>4 mm) have high nodal metastasis risk (30-50%) and SLN is less critical for staging as many warrant completion lymph node dissection regardless of SLN status.

Interpretation: Pathologic assessment includes multiple sections to identify micrometastases. Immunohistochemistry (S100, Melan-A, SOX10) enhances detection of small metastatic foci. Size of largest nodal deposit influences outcome: micrometastases (<0.1 mm) carry better prognosis than macroscopic (≥0.1 mm) disease. Presence/absence of extranodal extension also influences staging and prognostication.

Clinical Significance: Positive SLN upstages patients to stage III, fundamentally changing management. Node-positive patients warrant consideration of adjuvant systemic therapy (immunotherapy or targeted therapy) to improve distant disease-free survival and overall survival.

Prognostic Models and Refinement

Nomograms: AJCC TNM staging provides population-level prognostic data; however, individual patient outcomes vary. Melanoma nomograms incorporating additional factors (patient age, tumor location, presence of regression, lymphocytic infiltration) provide more precise individual risk estimates. Validated nomograms guide discussions regarding adjuvant therapy, surveillance intensity, and expected outcomes.

Molecular Prognosticators: Emerging evidence suggests tumor-infiltrating lymphocyte density, circulating tumor DNA burden, and specific mutation profiles (BRAF, NRAS, KIT) predict immunotherapy response and survival. Multigene expression profiles and tumor mutational burden are under investigation for prognostication. However, TNM staging remains standard for risk assessment and treatment guidance.

FAQ

Q: What does T3b N2a M0 mean?
A: T3b = primary tumor 2-4 mm with ulceration; N2a = 2-3 lymph nodes involved with micrometastases; M0 = no distant metastases. This is stage IIIB disease with approximately 45-50% 5-year survival.

Q: Is sentinel lymph node biopsy necessary for my melanoma?
A: Recommended for melanomas 1-4 mm thickness. SLN identifies occult nodal disease in 5-10% of cases, upstaging patients and guiding adjuvant therapy decisions. Thin (<1 mm) and thick (>4 mm) melanomas have different SLN indications.

Q: What stage is my melanoma if I have positive lymph nodes?
A: Any primary tumor with positive lymph nodes is at minimum stage III (regardless of T stage). Number of involved nodes, size of disease, and metastasis presence determine precise stage. Stage IIIA-IIIC show 40-78% 5-year survival depending on extent.

Q: Does melanoma staging determine treatment?
A: Yes. Stage I-II receive surgery alone typically. Stage III (node-positive) warrant consideration of adjuvant systemic therapy (immunotherapy or targeted therapy) improving survival. Stage IV requires systemic therapy (checkpoint inhibitors, targeted therapy) as primary treatment.

References

  1. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer 8th edition staging system. CA Cancer J Clin. 2017;67(6):472-492.
  2. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3622-3632.
  3. Balch CM, Soong SJ, Atkins MB, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004;54(3):131-149.
  4. Mihm MC Jr, Clark WH Jr. Histological identification and significance of the vertical growth phase (VGP) of cutaneous melanoma. Hum Pathol. 2015;46(2):281-290.
  5. Wong SL, Kattan MW, McMasters KM, et al. Sentinel lymph node biopsy for melanoma: prognostic value of staging the extent of lymph node involvement. Arch Surg. 2004;139(7):740-746.
  6. Cormier JN, Xing Y, Ding M, et al. Ethnicity and surgical treatment in melanoma. J Clin Oncol. 2006;24(12):1947-1955.
  7. Scolyer RA, Murali R, McCarthy SW, et al. Histologically negative sentinel lymph nodes in melanoma patients with regional metastases: a further argument for the sentinel lymph node biopsy. Ann Surg Oncol. 2007;14(10):2815-2824.
  8. Buzaid AC, Ross MI, Balch CM, et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a revised system. J Clin Oncol. 1997;15(3):1039-1051.
  9. Mackie RM, Bielsa I, Bufalini R, et al. Lentigo maligna and lentigo maligna melanoma. Melanoma Res. 1992;2(3):181-186.
  10. Kalady MF, White RR, Johnson JL, et al. Thin melanomas: predictive lethal indices of metastasis. Ann Surg. 2003;238(4):528-537.